Inside the institute looking at early cancer
24 July 2024Today sees the launch of the Early Cancer Institute at Cambridge. Its mission is deceptively simple: to detect cancer early enough to cure it.
Today sees the launch of the Early Cancer Institute at Cambridge. Its mission is deceptively simple: to detect cancer early enough to cure it.
Find out about groundbreaking cancer research at Cambridge, including our planned new hospital, how we're studying the earliest stages of cancer, how AI is helping fight the disease, and the patients playing a key role in our work.
Two-thirds of the public say they are very or somewhat worried about being told they have cancer – higher than for any other medical condition – according to polling released today.
Work will begin soon on a new hospital that will transform how we diagnose and treat cancer. Cambridge Cancer Research Hospital will treat patients across the East of England, but the research that takes place there promises to change the lives of cancer patients across the UK and beyond.
Ten outstanding Cambridge researchers have been elected as Fellows of the Royal Society, the UK’s national academy of sciences and the oldest science academy in continuous existence.
The University of Cambridge’s Early Cancer Institute – the UK's only research facility dedicated to understanding early cancer – has received a landmark £11 million donation to support its vital work in the fight against cancer.
A new test to help diagnose a condition that can lead to oesophageal cancer – developed by Cambridge researchers and trialled by the NHS – has reduced the need for invasive endoscopy in thousands of low-risk patients.
A man from Cambridge is the first to join the surveillance part of a clinical trial that could see routine screening for oesophageal cancer introduced into the NHS, potentially halving deaths from this cancer every year.
Leaders in fields from chemistry to cancer research and computing are among the Cambridge academics recognised today.
Marcel Gehrung, co-founder and CEO of rapidly growing Cambridge biotech company, Cyted, on revolutionising disease diagnostics and the challenges of building a business during a pandemic.